News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
859,717 Results
Type
Article (87357)
Company Profile (759)
Press Release (771575)
Multimedia
Podcasts (168)
Webinars (28)
Section
Business (233025)
Career Advice (4137)
Deals (39786)
Drug Delivery (134)
Drug Development (91233)
Employer Resources (202)
FDA (18270)
Job Trends (17394)
News (397318)
Policy (39919)
Tag
Academia (3003)
Academic (2)
Accelerated approval (17)
Adcomms (35)
Allergies (123)
Alliances (56979)
ALS (142)
Alzheimer's disease (1670)
Antibody-drug conjugate (ADC) (219)
Approvals (18278)
Artificial intelligence (475)
Autoimmune disease (65)
Automation (25)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (157)
Biotechnology (484)
Bladder cancer (122)
Brain cancer (50)
Breast cancer (469)
Cancer (3736)
Cardiovascular disease (331)
Career advice (3553)
Career pathing (37)
CAR-T (237)
CDC (53)
Cell therapy (661)
Cervical cancer (32)
Clinical research (75190)
Collaboration (1345)
Company closure (4)
Compensation (916)
Complete response letters (59)
COVID-19 (2947)
CRISPR (81)
C-suite (557)
Cystic fibrosis (132)
Data (4119)
Decentralized trials (2)
Denatured (60)
Depression (108)
Diabetes (444)
Diagnostics (7076)
Digital health (35)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (227)
Drug pricing (180)
Drug shortages (36)
Duchenne muscular dystrophy (197)
Earnings (98708)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (132676)
Executive appointments (975)
FDA (20641)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (13)
Funding (1211)
Gene editing (169)
Generative AI (45)
Gene therapy (528)
GLP-1 (1008)
Government (5371)
Grass and pollen (7)
Guidances (335)
Healthcare (20937)
HIV (48)
Huntington's disease (37)
IgA nephropathy (55)
Immunology and inflammation (238)
Immuno-oncology (19)
Indications (51)
Infectious disease (3177)
Inflammatory bowel disease (184)
Inflation Reduction Act (15)
Influenza (92)
Intellectual property (181)
Interviews (815)
IPO (17924)
IRA (59)
Job creations (5196)
Job search strategy (2864)
Kidney cancer (15)
Labor market (74)
Layoffs (634)
Leadership (32)
Legal (10148)
Liver cancer (91)
Longevity (12)
Lung cancer (532)
Lymphoma (256)
Machine learning (27)
Management (66)
Manufacturing (615)
MASH (130)
Medical device (14852)
Medtech (14873)
Mergers & acquisitions (22715)
Metabolic disorders (1128)
Multiple sclerosis (133)
NASH (23)
Neurodegenerative disease (219)
Neuropsychiatric disorders (59)
Neuroscience (2669)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (56)
Obesity (552)
Opinion (308)
Ovarian cancer (123)
Pain (160)
Pancreatic cancer (163)
Parkinson's disease (235)
Partnered (28)
Patents (404)
Patient recruitment (295)
Peanut (57)
People (66184)
Pharmaceutical (144)
Pharmacy benefit managers (26)
Phase I (23180)
Phase II (32657)
Phase III (24563)
Pipeline (2605)
Policy (289)
Postmarket research (3554)
Preclinical (10463)
Press Release (72)
Prostate cancer (187)
Psychedelics (51)
Radiopharmaceuticals (281)
Rare diseases (644)
Real estate (7420)
Recruiting (78)
Regulatory (27894)
Reports (64)
Research institute (2688)
Resumes & cover letters (650)
Rett syndrome (13)
RNA editing (15)
RSV (69)
Schizophrenia (131)
Series A (200)
Series B (148)
Service/supplier (30)
Sickle cell disease (79)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4318)
State (2)
Stomach cancer (17)
Supply chain (98)
Tariffs (90)
The Weekly (106)
Vaccines (1027)
Venture capital (66)
Weight loss (389)
Women's health (58)
Worklife (21)
Date
Today (104)
Last 7 days (583)
Last 30 days (2389)
Last 365 days (33702)
2025 (25256)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (80)
Alaska (7)
Arizona (299)
Arkansas (14)
Asia (50884)
Australia (8940)
California (9214)
Canada (2797)
China (863)
Colorado (391)
Connecticut (410)
Delaware (253)
Europe (116930)
Florida (1353)
Georgia (308)
Hawaii (3)
Idaho (67)
Illinois (801)
India (47)
Indiana (447)
Iowa (19)
Japan (304)
Kansas (123)
Kentucky (36)
Louisiana (20)
Maine (76)
Maryland (1249)
Massachusetts (6929)
Michigan (307)
Minnesota (554)
Mississippi (4)
Missouri (116)
Montana (33)
Nebraska (26)
Nevada (106)
New Hampshire (76)
New Jersey (2550)
New Mexico (32)
New York (2516)
North Carolina (1389)
North Dakota (10)
Northern California (4128)
Ohio (287)
Oklahoma (20)
Oregon (50)
Pennsylvania (1919)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (46)
South Dakota (1)
Southern California (3524)
Tennessee (148)
Texas (1443)
United States (34120)
Utah (273)
Virginia (243)
Washington D.C. (82)
Washington State (794)
West Virginia (4)
Wisconsin (95)
Wyoming (1)
There are 859,717 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPOs
UPDATE: MapLight Seeks $227M IPO For Neuropsych Portfolio
MapLight laid out the terms of its planned IPO in a regulatory filing on Monday, providing greater detail about what the funds will be used for.
October 7, 2025
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Pfizer Beat Out Two Other Metsera Suitors for Takeover
Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.
October 7, 2025
·
3 min read
·
Tristan Manalac
Obesity
Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail
Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.
October 7, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Amgen Hops on DTC Train To Offer Repatha at 60% Discount
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.
October 7, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Most Life Sciences Companies Not Planning New Investments After Tariffs: Report
A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”
October 7, 2025
·
3 min read
·
Dan Samorodnitsky
Business
BioSpace
Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit
The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.
October 7, 2025
·
2 min read
·
Angela Gabriel
Press Releases
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
October 7, 2025
·
3 min read
Press Releases
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
October 7, 2025
·
3 min read
Press Releases
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
October 7, 2025
·
2 min read
Press Releases
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
October 7, 2025
·
3 min read
1 of 85,972
Next
